Pancreatic cancer trials recruiting in Colorado
All Pancreatic cancer trials nationally
52
Recruiting in Colorado
24
Cities with sites
Cities in Colorado
Denver 30Aurora 22Littleton 7Colorado Springs 6Lakewood 6Boulder 5Durango 5Englewood 4Lone Tree 4Longmont 4Parker 4Pueblo 4
Recruiting trials in Colorado
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- DESTINY-PANTUMOUR04
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
- Integrated Cancer Repository for Cancer Research
- Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
- RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Shwachman Diamond Syndrome Registry and Study
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors